Supercharged T-Cells take on melanoma in early trial
NCT ID NCT01955460
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This early-phase trial tests whether giving patients with advanced melanoma immune cells that have been genetically modified to resist tumor-suppressing signals can help fight the cancer. The modified T-cells are given along with high-dose Interleukin-2, a drug that boosts immune activity. The study involves 34 patients and focuses on safety and whether the modified cells can be successfully produced and administered.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified T-cells (TGF-beta resistant) plus aldesleukin (high-dose Interleukin-2)
What this could lead to
If successful, this approach could point toward a more effective treatment for advanced melanoma by making immune cells resistant to tumor-suppressing signals.
What could go wrong
This is a very early phase 1 trial with only 34 participants, so it is primarily testing safety and feasibility. The modified T-cells may not work as expected, and high-dose IL-2 can cause severe side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.